BioCardia Files 8-K: Financial Statements & Exhibits
Ticker: BCDA · Form: 8-K · Filed: Oct 30, 2025 · CIK: 925741
| Field | Detail |
|---|---|
| Company | Biocardia, Inc. (BCDA) |
| Form Type | 8-K |
| Filed Date | Oct 30, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 B |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, exhibits, sec-filing
Related Tickers: BCDA
TL;DR
BioCardia dropped an 8-K with financial statements and exhibits. Standard filing.
AI Summary
On October 30, 2025, BioCardia, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update or disclosure related to the company's financial status and operations. No specific material events or transactions were detailed in the provided excerpt.
Why It Matters
This filing provides an update on BioCardia's financial reporting and exhibits, which is important for investors to stay informed about the company's financial health and operational disclosures.
Risk Assessment
Risk Level: low — The filing appears to be a routine disclosure of financial statements and exhibits, without any indication of significant negative events or material changes.
Key Players & Entities
- BioCardia, Inc. (company) — Registrant
- October 30, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 320 Soquel Way Sunnyvale, California 94085 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing by BioCardia, Inc.?
The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits'.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on October 30, 2025.
In which state is BioCardia, Inc. incorporated?
BioCardia, Inc. is incorporated in Delaware.
What is BioCardia, Inc.'s principal executive office address?
BioCardia, Inc.'s principal executive office is located at 320 Soquel Way, Sunnyvale, California 94085.
Does this filing indicate any specific new material events or transactions?
Based on the provided excerpt, the filing indicates 'Other Events' and 'Financial Statements and Exhibits' but does not detail specific new material events or transactions.
Filing Stats: 510 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2025-10-30 08:02:29
Key Financial Figures
- $0.001 B — h registered Common Stock , par value $0.001 BCDA The Nasdaq Capital Market Indicat
Filing Documents
- bcda20251030_8k.htm (8-K) — 25KB
- ex_879554.htm (EX-99.1) — 13KB
- 0001437749-25-032289.txt ( ) — 170KB
- bcda-20251030.xsd (EX-101.SCH) — 3KB
- bcda-20251030_def.xml (EX-101.DEF) — 11KB
- bcda-20251030_lab.xml (EX-101.LAB) — 15KB
- bcda-20251030_pre.xml (EX-101.PRE) — 11KB
- bcda20251030_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On October 30, 2025, BioCardia, Inc. issued a press release announcing the first patient enrolled at University of Wisconsin School of Medicine and Public Health in its ongoing Phase 3 CardiAMP HF II clinical trial. A copy of the press release is attached hereto as Exhibit 99.1 to this current report on Form 8-K. The information in this Item 8.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 BioCardia, Inc. press release dated October 30, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCARDIA, INC. /s/ Peter Altman, Ph.D. Peter Altman, Ph.D. President and Chief Executive Officer Date: October 30, 2025